CAR T-cell therapies hold a promising foothold in addressing unmet healthcare needs. Arcellx, a clinical-stage biotech company, is steadfastly exploring the potential of cell therapy in RRMM and generalized myasthenia gravis patients with its lead asset anito-cel.
 

Anito Cel, which continues to demonstrate no delayed neurotoxicity in both P-1 and P-II clinical trials for multiple myeloma, has received FTD, ODD, and RMAT designations, facilitating its regulatory milestones.

At PharmaShots today, we have Arcellx's Chief Scientific Officer, Heba Nowyhed, breaking down the company's pipeline and shedding light on recent presentations at ASH 2024.
 

Image Source: Canva

About the Author:

Heba Nowyhed

Heba joined Arcellx in November 2024 as Chief Scientific Officer. She has more than 15 years of leadership experience in drug development of cell and gene therapies, specifically CAR/TCR engineered T-cell products. Most recently, Heba held roles of increasing responsibility at IconOVir Bio, including Chief Scientific Officer, Senior Vice President of Research, and Vice President of Translational Research. As Chief Scientific Officer, she spearheaded the transition of the company's lead clinical drug product from preclinical to clinical stages, managed the research department, and drove development of a robust biomarker strategy. Prior to IconOVir Bio, she served as Senior Associate at Vida Ventures and Associate Director, Research at Kite, a Gilead Company. Heba began her career at La Jolla Institute for Immunology where she completed a postdoctoral fellowship. She was selected as a Woman to Watch finalist in the Los Angeles Business Journal 2021 Women's Leadership Awards. Heba received a PhD in Immunobiology as well as an MS and M.Ph. in Immunobiology from Yale University. She holds a BS in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles.

Related Post: CXO Talks: Cary Claiborne from Adial Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots